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Abstract
Background: Retroviruses have been observed to bud intracellularly into multivesicular bodies (MVB), in addition to the
plasma membrane. Release from MVB is thought to occur by Ca
2+-regulated fusion with the plasma membrane.
Principal Findings: To address the role of the MVB pathway in replication of the murine leukemia virus (MLV) we took
advantage of mousemodels for the Hermansky-Pudlaksyndrome (HPS)andGriscellisyndrome. In humans, thesedisordersare
characterizedbyhypopigmentation and immunologicalalterationsthatarecausedbydefectsinthebiogenesisandtrafficking
of MVBs and other lysosome related organelles. Neonatal mice for these disease models lacking functional AP-3, Rab27A and
BLOC factors were infected with Moloney MLV and the spread of virus into bone marrow, spleen and thymus was monitored.
WefoundamoderatereductioninMLVinfectionlevelsinmostmutantmice,whichdifferedbylessthantwo-foldcomparedto
wild-type mice. In vitro, MLV release form bone-marrow derived macrophages was slightly enhanced. Finally, we found no
evidence for a Ca
2+-regulated release pathway in vitro. Furthermore, MLV replication was only moderately affected in mice
lacking Synaptotagmin VII, a Ca
2+-sensor regulating lysosome fusion with the plasma membrane.
Conclusions: Given that MLV spreading in mice depends on multiple rounds of replication even moderate reduction of virus
release at the cellular level would accumulate and lead to a significant effect over time. Thus our in vivo and in vitro data
collectively argue against an essential role for a MVB- and secretory lysosome-mediated pathway in the egress of MLV.
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Introduction
Retroviruses such as the murine leukemia virus (MLV) and the
human immunodeficiency virus (HIV) have been reported to
accumulate in intracellular vesicles, called multivesicular bodies
(MVB). It has been proposed that budding into MVB followed by
release of the viral content could contribute to the overall amount
of viral dissemination [1–4], in addition to the ‘‘classical’’ egress
from the plasma membrane [5–8]. How retroviral particles reach
late endosomal vesicles has remained a matter of debate. In one
model, Gag would be sorted directly from the Golgi via a process
dependent on the AP-3 and the E3 ligase Posh [9–11]. Env may be
co-recruited to Gag via an interaction with TIP47, an effector of
the small GTPase Rab9 [12,13]. Downregulation of TIP47 as well
as Rab9 blocks HIV release [12,14]. In contrast, compelling
evidence has recently been reported that retroviral HIV Gag
accumulating in MVBs originates from the plasma membrane
[15–18]. Importantly, interference with endocytosis blocked the
accumulation of HIV Gag at MVBs, yet did not interfere with the
release of virus infectivity from cells [16,17]. Consistently, a recent
time-lapse microscopy study directly visualized the assembly and
budding of HIV at the plasma membrane [19]. Finally, a
compartment in macrophages with MVB-like features that
harbors infectious HIV was found to be continuous with the
plasma membrane [20,21].
While in some cell-types Gag reaches MVB-like compartments
either via the Golgi or by re-endocytosis from the plasma
membrane, a critical question remains as to whether viral particles
accumulating in intracellular compartments canlater be released by
fusion with the plasma membrane. Release may represent a
regulated event, and much excitement for a potential MVB
pathway has originated from the idea that cell-cell contact could
trigger MVB mobilization and polarized release [2,3,22]. Particu-
larly for antigen presenting cells such as dendritic cells and
macrophages, it has been proposed that interactions with T-cells
can mobilize MVBs to transport HIV directly to cell-cell contact
sites [22–24]. One way to induce the secretion of MVBs and
lysosomes is through Ca
2+ signaling. Treatment of HIV-infected
cells with Ca
2+ ionophores has been shown to dramatically increase
virus release although the mechanism is not well understood [9,25].
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2713There is substantial in vitro evidence that retroviruses can
accumulate within the lumen of multivesicular bodies (MVB), but
the relevance of an MVB release pathway in vivohas not been tested.
Here, we take advantage of severalmouse model of the Hermansky-
Pudlak syndrome (HPS) and Griscelli syndrome (GS), human
genetic disorders characterized by hypopigmentation and immu-
nological defects [26–28]. These defects are caused by a set of
autosomal recessive mutations that affect the proper biogenesis or
trafficking of MVBs and other lysosome-related organelles (LROs),
including melanosomes, platelet dense granules, and lytic granules.
The corresponding mice exhibit a light coat-color due to defects in
melanosome biogenesis causing defects in pigmentation. In
addition, prolonged bleeding times due to defects in the release of
platelet dense granules are also observed. In mice, HPS is caused by
a diverse set of 15 genetic mutations, 10 of which canbe categorized
into three distinct complexes called Biogenesis of Lysosome-related
Organelle Complexes (BLOC-1, 2, or 3) [28,29]. Defects in these
complexes lead to aberrations in the synthesis of LROs. 4 of the
remaining 5 mutations are known to affect the trafficking of vesicles
to and from LROs [28]. Two of these mutations (pearl and mocha)
affect subunits of the AP-3 complex, disrupting the trans-Golgi
sorting of membrane proteins to endosomes and leading to an
increased presence of lysosomal proteins (CD63, Lamp-1) at the
plasma membrane [30,31]. Cytotoxic lymphocytes of AP-3 mutants
are also unable to destroy target cells, due to the inability of
secretory granules to migrate along microtubules and polarize
towards immunological synapses [32,33].
In addition to HPS mutants, mutations in the gene encoding
Rab27a cause an autosomal recessive disease in humans called
Griscelli syndrome (GS) that is also characterized by hypopig-
mentation and immunological defects [34,35]. Unlike HPS
mutants, Rab27a mutant mice (ashen) generate normal secretory
granules, but these compartments are unable to fuse with the
plasma membrane during exocytosis [27,36,37]. In dendritic cells,
Rab27a is also required for fusion of secretory lysosomes with
phagosomes [38].
Because mouse models of the Hermansky-Pudlak syndrome and
the Griscelli syndrome exhibit general defects in MVB and
lysosome biogenesis, we have tested the ability of MLV to spread
in these mice. MLV replication was found to be only moderately
affected in mutant mice arguing against an essential role of these
genes in virus replication. Furthermore, visual and biochemical
analyses reveal no effect of Ca
2+ signaling on the kinetics of MLV
assembly and release. Collectively, these data argue against an
important role for MVB biogenesis and egress in the productive
replication and spread of MLV.
Results
MLV spreads in mouse models for the Hermansky-Pudlak
syndrome (HPS) and Griscelli syndrome (GS)
To test the contribution of a MVB pathway to the replication of
MLV in vivo, wildtype and mutant mice defective in melanosome
biogenesis were analyzed for their ability to support MLV
infection [26]. Mice lacking Rab27a (ashen) were compared to
the background strain C3H/HeJ. All other mice, lacking functional
AP-3 (pearl), BLOC-1 (pallid), BLOC-2 (ruby-eye), BLOC-3 (light-ear),
BLOC-2,3 (cocoa/light-ear), and the triple knockout BLOC-1,2,3
(pallid/cocoa/light-ear) were compared to their background C57BL6
strain. Mice were infected with 3610 ˆ3 infectious MoMLV virions
intraperitoneally 3 days after birth to bypass a strong humoral
antibody response that can completely control MLV infection in
adult mice [39]. At different time points post-infection, the mice
were sacrificed, bone marrow, spleen, and thymus were removed,
and genomic DNA was isolated and analyzed by real-time PCR to
quantify the number of MLV genomes. This copy number was
normalized to the number of copies of host actin-A1 in each
sample and subsequently to the number of cells. Viral replication
was first detected 10–14 days post-infection (Figure 1). Bone-
marrow, spleen and thymus became infected simultaneously,
differing from reports published for a MLV variant that initially
targets the bone-marrow [40]. Infection levels were highly
reproducible beyond day 14, and day 18 was chosen for an end
point analysis of MLV replication levels.
For all mutant mice tested, a moderate up to two-fold %
decrease in viral load was seen in all three organs compared to
wildtype (Figure 2). In some cases, this moderate reduction was
found to be statistically significant by non-parametric Mann-
Whitney double T-Test with a confidence level of 95% (indicated
by * in Figure 2).
MLV is efficiently released from primary macrophages
derived from HPS mice
In order to determine the effects of HPS factors in virus release
on a cellular level, bone-marrow derived macrophages were
isolated from wildtype and mutant mice and tested for their ability
to release virus (Figure 3A, B). Although the level of infection in
the macrophages from all mice varied slightly, none of the three
mutants displayed a decrease in viral output compared to
wildtype. In fact, after normalizing the amount of virus released
to the level of infection in the corresponding producer cells,
macrophages from the pearl (AP-3) and triple knockout BLOC-
1,2,3 mutants released two to four fold more virus (Figure 3C).
Figure 1. Detection of MLV infection in wildtype C57BL/6 mice. C57BL/6 mice were infected with MoMLV by intraperitoneal injection 3 days
after birth and sacrificed at indicated days after infection. Genomic DNA from each organ was independently isolated and real-time PCR was
performed to quantify the number of integrated proviral MLV genomes. MLV was first detected by day 11, and mice became viremic by day 14. Day
18 was selected as a suitable timepoint to sacrifice all mice for each in vivo experiment.
doi:10.1371/journal.pone.0002713.g001
Role of MVB in MLV Release
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siRNA in HEK 293 cells with efficiency as high as 95%, released
MLV infectivity and capsid were unchanged (Figure 4). These
results demonstrate that the mutation of HPS factors and the
absence of functional AP-3 does not hinder viral egress, but in
some cell-types actually enhances release.
Ca
2+-regulated release of secretory lysosomes does not
significantly contribute to MLV release in vitro and in
vivo.
Secretion of MVBs and other secretory lysosomes is regulated
by Ca
2+ in a process that is controlled by Synaptotagmin VII (Syt
VII) [41,42]. To test for a potential role for Syt VII in MLV
release, we asked if MLV Gag would co-localize to Syt VII-
positive vesicles. MLV assembly was visualized in HEK 293 cells
using fusion proteins to MLV Gag and Env as previously described
[3]. When Syt VII-YFP was co-expressed, a co-localization
particularly with peripheral lysosomal vesicles [43] was observed
(Figure 5A, B). Because Syt VII-YFP like the endogenous protein
localizes to CD63 containing vesicles [43,44], this co-localization
raised the question if MLV is released via Syt VII-dependent
secretion of lysosomes.
Secretion of lysosome related organelles is stimulated in
response to a rise in intracellular Ca
2+ and can be induced by
Ca
2+ ionophores and cAMP [41,45]. Two previous studies have
reported increased HIV particle release in response to ionomycin
treatments [9,25]. We predicted that Ca
2+ driven MVB fusion
with the plasma membrane would lead to the increased exposure
of viral antigens at the cell surface as well as the increased secretion
of intralumenal virus like particles into the culture supernatant. To
this end we monitored MLV Gag-GFP distributions in single cells
using live time lapse wide-field fluorescence imaging. The addition
of 10 mM ionomycin demonstrated no effect on Gag-GFP delivery
to the cell surface from intracellular sources (data not shown). In
addition we applied total-internal reflection fluorescence micros-
copy (TIR-FM) to detect the possible fusion of endolysosomal
vesicles carrying viruses with the plasma membrane. TIR-FM
utilizes evanescent waves that are produced when light is totally
reflected at the glass-water interface. Because these waves decay
exponentially from the interface, they penetrate only to a depth of
approximately 100 nm into the sample medium. Thus TIR-FM
can be used to fluorescently excite the dorsal face of the cell to
ideally monitor events occurring specifically at or near the plasma
membrane. Using TIR-FM, we found no evidence of Gag-positive
MVB fusion with the cell surface in response to ionomycin
(Figure 5C).
In parallel, we harvested the culture supernatants after
ionomycin and cAMP treatment of HEK293 cells producing a
Lac-Z encoding MLV variant or primary macrophages producing
infectious wildtype MLV. In both experiments, we observed no
significant difference in virus or virus-like particle release between
treated and untreated cells (Figure 5D, E). Moreover, the
expression of the dominant-negative C2A domain of Syt VII
had no effect on MLV release from HEK 293 cells (Figure 5F).
Figure 2. MLV spreading in mouse models for Hermansky-Pudlak and Griscelli syndromes. Wildtype and mutant mice were infected with
Moloney MLV by intraperitoneal injection 3 days after birth. Bone marrow, spleen, and thymus were harvested 18 days post-infection and the
genomic DNA analyzed. The copy number for proviral MLV was normalized to cell numbers using internal standards for actin A1. Rab27a (ashen)i s
compared to its wildtype background C3H/Hej, while the remaining AP-3 (pearl), BLOC-1 (pallid), BLOC-2 (ruby-eye), BLOC-3 (light-ear), double mutant
BLOC-2,3 (cocoa/light-ear) and triple mutant (pallid/cocoa/light-ear) are compared to C57BL/6J. The statistical analysis with standard deviations is
presented in the lower panel, in which infection levels observed in both wild-type background mice are set to 100%. Values labeled with an asterisks
(*) indicates statistically significant differences to wildtype using the non-parametric Mann-Whitney double T-Test with a confidence level of 95%.
doi:10.1371/journal.pone.0002713.g002
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PLoS ONE | www.plosone.org 3 July 2008 | Volume 3 | Issue 7 | e2713Figure 3. MLV release from bone marrow derived macrophages is enhanced in HPS mutants. (A) Percentage release of MoMLV into the
supernatant by chronically infected macrophages relative to wildtype. Macrophages from respective mice were chronically infected for 7 days,
washed extensively with PBS; and supernatants were harvested after 48 hours and titered on DFJ8 cells. Genomic DNA from DFJ8 cells was extracted,
and proviral insertions were quantified by real-time PCR. (B) Percentage infection of macrophages by MoMLV. Genomic DNA from chronically
infected macrophages previously described were extracted and quantified by real-time PCR. (C) The amount of MoMLV released in the supernatant of
macrophages was normalized to the relative amount of infection of producer macrophages. Error bars represent standard deviations from n=6
independent experiments. The levels of infection observed for C57BL/6J were set to 100%.
doi:10.1371/journal.pone.0002713.g003
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we tested MLV spread in Syt VII knockout mice [46]. MLV
spread was moderately reduced in mice lacking Syt VII, a result
deemed significant by a non-parametric Whitney-Mann double T-
test (Figure 5G, H).
Discussion
In this study, we have conducted in vivo, ex vivo, and in vitro
experiments that collectively argue that a MVB-mediated pathway
of viral egress does not play an essential role in the dissemination
of MLV. In vivo, BLOC-1,2,3, AP-3, Rab27a, and Syt VII mutant
mice sacrificed at 18 days post-infection exhibited only a moderate
decrease in viral load in the bone marrow, spleen, and thymus
when compared to wildtype mice. At cellular level, MLV release
from infected macrophages lacking AP-3, Rab27a, or BLOC-1,2,3
was not inhibited, but rather enhanced when compared to
wildtype. These data suggest that the Golgi-endosomal sorting
pathway plays an inhibitory role in MLV release. Finally, we
demonstrated in vivo and in vitro that the fusion of secretory
lysosomes with the plasma membrane in response to elevated
calcium levels do not increase the level of MLV release.
In recent years, a number of groups have demonstrated that
both HIV and MLV have the ability to accumulate and bud
intracellularly into the lumen of MVB in vitro. It had been
speculated that viruses accumulating within this compartment may
contribute to the overall viral dissemination through a MVB-
mediated pathway of virus release, similar to the release of
exosomes, small 50–200 nm vesicles that accumulate in MVBs
and are released into the culture supernatant [4,47]. However, our
studies on MLV spread in vivo using mouse models of the
Hermansky-Pudlak syndrome does not support an important role
for an MVB-mediated release pathway. These mutant mice were
originally identified based on changes in the coat-color indicating
defects in the biogenesis of melanosomes, a specialized MVB
found in keratinocytes that carries pigment [48]. At least in the
case of pearl (impaired in AP-3) and ashen mice (impaired in
Rab27a), a general defect in the biogenesis and release of secretory
lysosomes has been observed [32,33,36,37]. However, both mice
became infected with MLV infection levels similar to wild-type or
just moderately reduced. When one considers that it takes two
weeks before MLV infection spreads into all organs, implying
many consecutive rounds of infection, an essential role of these
factors in virus dissemination is unlikely. In vivo, even moderate
effects at the single cell level should accumulate over time into a
sizeable phenotype. In contrast, in vitro cultured primary
macrophages showed enhanced virus release. MLV spreading
was also not affected in mice lacking BLOC components. Recent
data suggest that BLOC mice may not exhibit general defects in
the biogenesis of secretory lysosomes, but rather play a specific role
in the biogenesis of melanosomes [49].
While ourdataargue against an important role ofMVBs in MLV
release, they cannot exclude the possibility that this pathway
contributes to virus release in specific cell types. In our study,
newborn mice were infected that lack a fully developed immune
system and therefore lack fully differentiated antigen presenting
cells. Hence, we cannot exclude the possibility that MLV uses an
MVB pathway during the infection of adult mice, in which the
disease is quickly controlled by an antibody mediated response [39].
In contrast to MLV, HIV may potentially use a dissemination
pathway involving MVB and secretory lysosomes [9,25]. Func-
tional AP-3 was reported to be critical for the sorting and release of
HIV Gag from cells suggesting that trafficking of HIV Gag from
the Golgi towards late endosomes/MVBs is necessary for HIV
release [10]. However, recent reports provide evidence that the
accumulation of HIV in late endosomal membranes is due to
endocytosis of HIV virions budding at the plasma membrane and
did not lead to a release of infectious virions [16,17,19]
questioning a role of MVB in HIV release. In fact, these MVB-
like compartments filled with infectious HIV as observed in
macrophages are continuous with the plasma membrane [20,21].
Finally, ionomycin treatment has been shown to stimulate HIV
release [9,25]. However, in the case of MLV, we did not detect
any increases in virus release under such conditions. To further
study this in vivo, we utilized the Syt VII knock out mouse model.
Syt VII is a membrane protein found on lysosomal membranes
known to regulate lysosomal exocytosis and the fusion of secretory
granules with the plasma membrane through calcium signaling
[42,46,50]. Although we demonstrate that Syt VII colocalizes with
both MLV Gag and Env, we could not see a strong block to the
spread of MLV in Syt VII knockout mice or in cells expressing
dominant negative Syt VII C2A. Thus, our data collectively argue
against a functional role for MVB- and secretory lysosome-
mediated pathway in the egress of MLV in neonatal mouse model.
Figure 4. Silencing of AP-3d subunit does not effect MLV
release. (A) HEK293 cells were transfected with siRNA targeting
luciferase (negative control), AP-3d subunit or GFP (positive control).
24 h later these cells were transfected with plasmids encoding full-
length MLV expressing Env-GFP. 48 h later the infectivity as well as p30
MLV capsid released into the supernatant was determined. While
targeting AP-3 has no effect on MLV release, targeting the GFP within
the Env and full-length genome messages results in the inhibition of
virus release. (B) Western blot of HEK293 cells lysates treated with AP-3d
or luciferase siRNA using AP-3d and tubulin (loading control) specific
antibodies.
doi:10.1371/journal.pone.0002713.g004
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Mice:
Pearl, pallid (pa), ruby-eye (ru), light-ear (le), cocoa/light-ear (co/
le), pallid/cocoa/light-ear (pa/co/le), ashen (ash) were kindly
provided by Richard Swank (Roswell Park Cancer Institute,
Buffalo, NY) [26,28]. Wildtype C57BL/6 and C3H/Hej mice were
from JAX (Jackson Laboratory, Maine). Synaptotagmin VII
(sytVII) mice [46] were kindly provided by Norma Andrews (Yale
University, New Haven, CT). Mice were handled according to the
institutional guidelines for animal husbandry and experiments.
In Vivo Mouse Experiments:
Wildtype and mutant mice were infected with 20 ml Moloney
MLV (MoMLV) stock [51] by intraperitoneal injection 3 days
after birth. When titered on susceptible DFJ8 cells [52], 20 ml
corresponded to 3610
3 integrated MLV genomes. A 10 fold lower
amount of virus resulted in the infection of about half of the mice
Figure 5. MLV release is not mediated by secretory lysosomes in a Ca
2+ dependent manner. (A) A confocal z-slice through the center of a
HEK293 cell showing MLV Gag-CFP particles (green) accumulated within the interior of a swollen Syt VII-YFP positive vesicle (red) under conditions of
infectious virus production. White arrows indicate areas of co-localization. (B) An experiment as in (A) showing MLV Env-YFP (green) localized to
peripheral vesicles (white arrows) positive for Syt VII-CFP (red). Image is a 3-D reconstruction of a confocal z-stack. (C) Individual frames from a time-
lapse movie by TIR-FM of a 293 cell generating Gag-CFP-labeled MLV and treated with 10 mM ionomycin. Images indicate pre-treatment (left panel),
10 min (middle panel) and 20 min (right panel) after ionomycin treatment. Size bar corresponds to 10 mm. (D) Viral titers of supernatants harvested
from 293 cells generating LacZ-encoding MLV after incubation for 60 min in normal growth media, media containing 10 mM ionomycin, and media
containing 1 mM di-butyryl-adenosine cAMP. (E) Chronically infected mouse macrophages from C57BL/6, seven days post-isolation, were washed
extensively and incubated for 30 min in media, media containing 10 mM ionomycin, or media containing 1 mM di-butyryl-adenosine cAMP.
Supernatants were harvested and titered on DFJ8 cells prior to quantitative real-time PCR to detect proviral insertions. (F) Transfection was
performed as for (C) in the additional presence of 25 ng of parental plasmid (vector alone) or plasmids encoding YFP-tagged full-length, dominant
negative C2A domain of Syt VII or control Syt I, respectively. (G) Wildtype C57BL6/J (B6) and Syt VII mutant mice infected by intraperitoneal injection
with Moloney MLV 3 days after birth. Real-time PCR was performed on genomic DNA extracted from indicated organs to detect MLV insertions as
previously described. * denotes statistically significant differences from wildtype by non-parametric Mann-Whitney double T-Test with a confidence
level of 95%. (H) Percentages of (G) for each organ.
doi:10.1371/journal.pone.0002713.g005
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reproducibly infect all mice in a study group. Mice were sacrificed
18 days post-infection, and bone marrow, spleen, and thymus were
removed and homogenized. Genomic DNA was isolated by
Qiagen DNAeasy from each organ separately, and proviral
integrations quantified by real-time PCR (SYBR-GREEN; Bio-
Rad, Hercules, CA) using primers for MLV LTR [53] and parallel
standards for cytochrome b and ActinA1. The copies of MLV
proviral genomes were normalized to the number of ActinA1
copies per cell. Towards this end, the number of cells was
determined prior to DNA preparation and RT-PCR. To test the
significance of our results, we performed a non-parametric
Whitney-Mann double T-test using Graph Prism version 4.00.
Macrophage Experiments:
Primary mouse macrophages were generated by isolating the
bone marrow from femurs of wild-type and mutant mice. The
resulting cells were then plated onto non-tissue-culture treated 6-
well plates at a density of 10
6 cells per well in macrophage culture
medium containing RPMI 1640 medium supplemented with 20%
L-cell supernatant and 10% FBS. After two days, the macrophages
wereinfectedwithMoMLVinthepresenceof5 mg/mlpolybreneat
a MOI of 1. At day 7 post-infection, macrophages were washed
extensively five times with phosphate buffered saline. Macrophages
were then incubated in 1 ml macrophage culture media and
supernatants collected after 48 hours. Genomic DNA was then
isolated from the producer macrophages, and the resulting
supernatants were used to infect DFJ8 cells. After 2 days, genomic
DNA from the infected DFJ8 cells was isolated. The number of
copiesof integratedMLV andcellular actinA1from genomic DNAs
of both producer macrophages and corresponding target DFJ8 cells
were then quantified by real-time PCR as described above.
Budding Assays:
1610
6 HEK 293 cells per 35 mm dish were transfected using
FuGene 6 as previously described [3] with 400 ng each of MLV
Gag-Pol, Env, and LTR-LacZ with or without 50 ng of plasmids
encoding full-length Syt VII, dominant-negative Syt VII C2A
domain, control Syt I C2A domain [42]. At 24 hours post-
transfection, cells were washed, trypsinized, and diluted two-fold in
fresh media before replating. Culture supernatants containing
virus were collected 24 hours later (48 hours post-transfection),
filtered and titered by serial dilution on DFJ8 cells. Alternatively,
HEK 293 cells, transfected as above, were washed five times and
incubated in the appropriate growth media containing ionomycin
or di-butyryl adenosine cAMP (Sigma, St. Louis, MO) for 1 hour.
To reduce the effects of entry on virus titration, culture
supernatants were either diluted 1:10 in normal growth media
or viruses were sedimented through a 15% sucrose cushion by
centrifugation at .20,0006g for 2 h prior to resuspension in 1 ml
media. In the AP-3 silencing experiment, 5610
5 HEK293 cells in
48 well plates were transfected with 80 nM siRNA (Samchully
Pharm. Ltd., Seoul, Korea) specific to AP-3d subunit, GFP
(positive control) or luciferase (negative control) using Lipofecta-
mine 2000 (Invitrogen, CA). 24 hours post transfection cells were
split 1:4 into 4 wells of a 48 well plate and transfected again as
above with 100 ng plasmid encoding full-length MLV genome
carrying a GFP insertion into the envelope protein. After an
additional 48 h, the culture supernatants were harvested and
applied onto DFJ8 for MLV titration. DFJ8 cells were harvested
48 h after infection and analyzed by FACS to determine the
number of GFP-positive cells. Fold inhibition in release was
calculated using a ratio of the percent GFP positive cells from
experimental samples transfected with AP-3d-specific or GFP-
specific siRNA and those transfected with luciferase control
siRNA. Downregulation of AP-3d was tested by western blot
using antibodies to d subunit of AP-3 (120 kDa; BD transduction
laboratories). The sense strand siRNA sequence used for targeting
AP-3 was 59 UCUGCAAGCUGACGUAUUUdTdT-39, GFP
was 59-CGGCCACAAGUUCAGCGUGUCdTdT-39 and lucif-
erase was 59-CUUACGCUGAGUACUUCGAAAdTdT-39.
Live imaging and fluorescence microscopy:
Fluorescence microscopy was carried out as previously de-
scribed [3,54] using the 1006objective of a LSM510 confocal
microscope equipped with a Zeiss Axiovert 100 M base (Zeiss
Microimaging, Jena, Germany). Live cell imaging using total
internal reflection fluorescence microscopy was as previously
described [55] using the 606(1.45 NA) oil-immersion objective of
a modified Olympus IX-70 microscope. Drugs were added during
imaging by 1:10 dilution into the DMEM media to achieve the
appropriate final concentration. Synaptotagmin VII-YFP was
described previously [44].
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